Introduction {#s0001}
============

Among essential workers selflessly serving during the coronavirus disease 2019 (COVID-19) pandemic are health-care providers (HCPs). That frontline HCPs are caring for contagious patients with inadequate personal protective equipment (PPE) is well known. Many HCPs have resorted to handmade masks to address this need. Unfortunately, the effectiveness of such masks as PPE is uncertain \[[@cit0001]\].

COVID-19, like other coronaviruses, is an enveloped, positive-sense RNA virus \[[@cit0002]\]. It is thought to be highly contagious with human-to-human transmission occurring through respiratory droplets expelled during coughing or sneezing from an infected individual that are then breathed in by the next host \[[@cit0003]\]. In the early stages of infection, patients experience symptoms of the upper respiratory tract. For those who experience a mild infection, the illness does not progress \[[@cit0003]\]. For others, illness can progress to a more serious lower respiratory infection, potentially turning fatal \[[@cit0003]\].

Although not conclusive, some evidence suggests that higher viral load may be associated with more severe clinical outcomes for patients infected with COVID-19 \[[@cit0004]\]. Similar findings suggesting that high viral load in the nasal passages may be an indicator of severe illness were obtained from analyses of patients infected with SARS-CoV, a distinct coronavirus, during the 2003 global outbreak \[[@cit0005]\].

Taken together, the lack of adequate and readily available PPE for first-line HCPs, the manner in which COVID-19 is transmitted, and the potential impact of viral load on patient outcome all indicate a need for prophylaxis targeting the upper respiratory tract to mitigate the impact of multiple exposures to the virus.

A safe prophylaxis consisting of a mouth rinse that can be administered to effectively cleanse the back of the throat in combination with a solution administered nasally to cleanse the nasal and nasopharyngeal passages may successfully target the tissues of the upper respiratory tract likely associated with initial infection \[[@cit0006]\].

Due to their microbicidal properties and their tolerability as cleansers of these same tissues, solutions of acidified sodium chlorite may be appropriate for such prophylactic use.

Acidified sodium chlorite is used as an antiseptic in the industrial setting for food processing and water purification \[[@cit0007]\]. It has been evaluated or used more recently in over-the-counter oral or nasal cleansing solutions \[[@cit0008]--[@cit0010]\].

Acidified sodium chlorite (ASC) solution, or sodium chlorite (NaClO~2~) in aqueous solution with acid (H^+^), forms semi-stable chlorous acid (HClO~2~). Chlorous acid degrades to chlorine dioxide (ClO~2~), which, over time, further degrades to chlorite (ClO~2~¯) and ultimately, chloride (Cl¯) \[[@cit0007]\]. Exposure to light and higher temperatures accelerates the degradation process \[[@cit0011]\]. Chlorous acid and ClO~2~ are thought to be responsible for the microbicidal action of ASC \[[@cit0007]\].

Microbicidal properties of HClO~2~ and ClO~2~ {#s0002}
=============================================

HClO~2~ has demonstrated potent virucidal activity *in vitro* with \<4 ųg/ml of HClO~2~ effectively inactivating enveloped viruses at a pH consistent with the range observed in human nasal mucosa \[[@cit0012],[@cit0013]\]. HClO~2~ also seems to have limited cytocidal effects at greater than effective virucidal concentrations, suggesting its potential as a strong and safe disinfectant when present at low concentrations \[[@cit0012]\].

ClO~2~ has also demonstrated virucidal properties *in vitro*, including against coronaviruses, with a 0.004% (wt/vol %) solution of ClO~2~ effectively inactivating 100% of SARS-CoV in wastewater after exposure for 5 minutes, and inactivating 94.4% of the virus after exposure of 1 minute \[[@cit0014]\].

Additionally, ClO~2~ gas derived from ASC has been shown to have potent virucidal properties *in vivo*, specifically against influenza A viral infection in mice \[[@cit0015]\]. Mouth rinse studies of ClO~2~ solutions derived from ASC have demonstrated antibacterial and antifungal properties when used in people. These solutions have ranged from 0.003% to 0.016% (wt/vol %) ClO~2~ \[[@cit0009],[@cit0010]\]. A study of 0.14% ASC solution (ClO~2~ percentage not specified) demonstrated effective antibacterial action on saliva for up to 5 hours after single administration when patients rinsed with solution for 1 minute before expectorating \[[@cit0008]\]. Adverse events in the above studies were minor, if any, with taste disturbance being the most frequent \[[@cit0009]\].

Published findings on the use of ASC/ClO~2~intranasal solutions in humans are not available at this time. However, tolerability data-on-file (2017) shared by Sinox Pharma, Inc. show that a 0.008% (wt/vol %) ClO~2~ solution derived from ASC is nonirritating when administered as an intranasal cleanser to individuals with sub-clinical or clinical sinusitis.

Safety and tolerability {#s0003}
=======================

It is important to note that consuming solutions of ASC or ClO~2~, particularly those containing high concentrations of either compound, is inadvisable and may cause serious harm \[[@cit0016]\].

In 2000, the World Health Organization (WHO) published the International Programme on Chemical Safety (IPCS) derived recommendation of a tolerable daily intake of 0.03 mg of chlorite by kg weight, per day. Based on the IPCS recommendation, the WHO set a quality guideline value of 0.7 mg/L for chlorite in drinking-water \[[@cit0007]\].

In a study of adult male and female African Green monkeys, a daily dose of 9 mg/kg of ClO~2~ ingested through drinking water seemed to strongly inhibit thyroid synthesis \[[@cit0017]\].

However, more recent evaluations in animals and humans demonstrate that exposure to low concentrations of ASC or ClO~2~ (≤0.2% and \<0.02%, respectively) such as those found to be effective in human mouth rinse studies are well tolerated \[[@cit0008]--[@cit0010],[@cit0018]\].

Further evaluation of both safety and effectiveness when such solutions are employed for prophylactic use in humans to mitigate the effects of multiple exposures of COVID-19 is strongly advised.

ASC/ClO~2~ PPE suggested protocol {#s0004}
=================================

Interventions {#s0004-s2001}
-------------

The protocol proposed here ([Table 1](#t0001){ref-type="table"}) is for use in the hospital setting by HCPs treating patients presumed to be infected with COVID-19. Table 1.Proposed prophylactic protocol for nasopharyngeal and oropharyngeal cleansing when anticipating treatment of patients presumed or confirmed to have COVID-19. Nasopharyngeal and Nasal Cavity Cleansing (Snoot!™)Oropharyngeal and Oral Cavity Cleansing (DioxiRinse™)**Preparation**Follow package instructions to 'Mix Snoot!' (Sinox Pharma, Inc.) prior to first shift in relevant health-care settingLet prepared solution stand ≥10 minutes prior to first useFollow the package instructions to mix DioxiRinse (Frontier Pharmaceutical, Inc.), mixing a total of 15-20 ml of solution for immediate use.Let prepared solution stand for between 30 and 45 seconds prior to use**Administration**Follow package instruction for 'Use Snoot!' Briefly:Spray solution into each nostril while inhaling and holding opposing nostril closed (each spray from the included spray bottle delivers \~0.1 ml solution)Gently blow nose after 1 minuteExpectorate any solution drained into the throatSpray solution a second time into each nostril while inhaling and holding opposing nostril closedGently blow nose after 1 minuteExpectorate any solution drained into the throatDiscard solution after 12 hoursGargle as far into back of throat as possible for 30 secondsRinse oral cavity for 5--10 more secondsExpectorate**Repetition**Every 3 hours, up to 4 times a shift in 12 hours, including first use immediately prior to start of shift**On Maximal Use**Because nasal cleansing with a ClO~2~ solution will be coupled with use of an oral rinse, also a ClO~2~ solution, the maximum recommended use of either product should not exceed 4 administrations within a 24-hour period.**Special Considerations**If irritation occurs at later uses relative to earlier ones in a 12-hour period, discard remaining solution and remix fresh solution as directed; strength of solution increases over time, not exceeding 75 ppm ClO~2~ at 12 hours.--

As preparations of ClO~2~ solution derived from ASC for use in the mouth and nose are commercially available, two such products are suggested for use in this protocol.

The first is Snoot™ (Sinox Pharma, Inc.) at the 'Original' strength. This formulation yields between 60 parts per million (ppm) and 75 ppm (\~0.01% wt/vol) ClO~2~ over the course of 12 hours, the usage period suggested here. According to data-on-file shared by Sinox Pharma, Inc., this formulation may cause nasal discomfort in some individuals but is unlikely to cause inflammation.

The second recommended product is DioxiRinse™ (Frontier Pharmaceutical, Inc.) to be used at the 'Standard Strength' yielding a concentration of \~40 ppm (0.006% wt/vol) ClO~2~.

Use will entail daily preparation of solutions for cleansing of the mouth, throat, and nasal passages of participants. Once daily preparation is advised for nasal cleansing. Preparation immediately prior to each use is advised for oral cleansing. Both products should demonstrate virucidal activity and be well tolerated at these strengths/concentrations.

Contraindications {#s0004-s2002}
-----------------

Individuals with allergies to any of the ingredients in either product including but not limited to cinnamon and mint along with individuals experiencing thyroid dysfunction or poor tolerance to either product should be excluded.

Pre-administration {#s0004-s2003}
------------------

HCPs should be offered the interventions described here as supplemental PPE and should provide their freely given consent to participate in the prospective evaluation of this protocol, with no risk to their professional standing should they refuse to participate.

Exceptions to protocol {#s0004-s2004}
----------------------

In the event that an HCP has direct exposure to expelled particles from a cough or sneeze of an individual with presumed COVID-19, immediate cleansing using both products is suggested, even if the recommended maximum use of 4 times in a 12-hour period is exceeded. However, \>6 administrations in a 24-hour period are strongly discouraged.

Reporting {#s0004-s2005}
---------

Participants should report any adverse events experienced to their hospital administrators for immediate recording and reporting.

Discussion {#s0005}
==========

The lack of sufficient PPE to protect first-line HCPs from infection has elevated the need to identify a safe and effective prophylaxis to mitigate the impact of multiple exposures to this virus. Only one of several potential solutions to this problem has been presented here.

Other proposed options for prophylaxis include a protocol detailing the use of a highly diluted form of povidone-iodine (PVP-I) solution as a mouth rinse and nasal spray \[[@cit0019]\], and the administration of nitric oxide gas to HCPs at the start and end of their shifts \[[@cit0020]\].

Each potential prophylactic avenue is associated with benefits and challenges ([Table 2](#t0002){ref-type="table"}). Table 2.Benefits and challenges of potential prophylactic interventions to mitigate the impact of HCP exposure to COVID-19 virus.Potential ProphylaxisBenefitsChallenges**ASC/Chlorine Dioxide Solution**Uses two readily available commercial productsEach product has been found to be safe and tolerable when used individuallyEasy to prepare and administerSuggested use of 4 times per shift may be untenable for overextended HCPs with little time to spare between patients for personal careLack of tolerability to the nasal cleanser may preclude use by some individualsThe two products have not previously been evaluated for safety when used in tandem or for this specific purpose**PVP-I Solution**Readily available and comparatively affordable active ingredient component of solutionEasy to prepare, store, and administerSuggested use of 4 times per shift may be untenable for overextended HCPs with little time to spare between patients for personal careUse may result in temporary staining of nasal and oral tissuesSolution has not previously been evaluated for safety when used as both an oral rinse and a nasal spray, or when used for this specific purpose**Nitric Oxide Gas**Compelling administration frequencyExposure to nitric oxide gas can prove toxic if not carefully monitored and controlledWill require expensive, specialized equipment to administer

However, none of the challenges posed for any of these options are insurmountable. And HCPs can only benefit from having multiple effective options to choose from. Indeed, the three described here may be too few.
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